The 35th CINP World Congress of Neuropsychopharmacology

Session information

[CINP2024] Spotlight Session

CINP2024 » Spotlight Session

Spotlight Session 9
Introducing CINP's Global Networking Communities

Sat. May 25, 2024 1:00 PM - 2:00 PM Room 5 (G409)

Chair: Joseph Zohar (National Post-Trauma Center, Research Foundation by the Sheba Medical Center, Israel)

Overview:
CINP has recently formed six Global Networking Communities (GNCs) to provide a collaborative and inclusive environment for those with shared subspecialist interest to network with global peers, develop and obtain funding for collective research projects, pursue educational goals, raise awareness of new treatment modalities and build symposia proposals for CINP World Congresses.
Membership of the GNCs is open to all CINP members in good standing, who are eligible to join a maximum of two communities. The first six GNCs to be formed cover the following subspecialist fields:
Difficult to Treat Depression, Digital Intervention, Fast Acting Medications/Psychedelics, Neuromodulation, OCD Spectrum, Precision Psychiatry.
In this session, four of the GNC leaders will introduce their communities and provide an overview of the activities they have planned for the next 12 months.
Audience members will have the opportunity to ask questions and to propose areas of activity for the various communities.

*Gabriella Gobbi1 (1. McGill University)

Prof Gabriella Gobbi is a Professor in the Department of Psychiatry at McGill University, Montreal. She leads a laboratory of basic science (Neurobiological Psychiatry Unit) and works as a Staff Psychiatrist at the Mood Disorder Clinic of the McGill University Health Center.
Her laboratory focuses on understanding the pathophysiology of major depression and sleep related disorders and in the discovery of new treatments and cures for them. She is particularly known for her work on Psychedelics for Anxiety, the association between cannabis use and depression in adolescence and the use of Melatonin MT2 receptor agonsists for pain and insomnia.
Dr. Gobbi is author of more than 90 highly cited manuscripts in high impact journals, 20 book chapters, one book and holds two international patents in psychopharmacology. She has received several fellowships, won many prizes and serves as a reviewer/editor for many journals.

*Kim Q. Do1 (1. Center for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, Lausanne, Switzerland)

Prof. Kim Q. Do is Professor for Psychiatric Neuroscience at Lausanne University. Trained as neurobiologist at the Polytechnical Federal School (ETHZ) and Brain Research Institute in Zurich, she is interested in bridging basic neuroscience with problems of clinical psychiatry.
She set up a translational research program aimed at a better understanding of the causes and mechanisms leading to schizophrenia phenotypes in order to develop markers for early diagnosis, new drug targets as well as preventive and therapeutic measures.
Dr. Do’s pioneering and evolving focus on redox dysregulation and oxidative stress in psychosis has a growing influence on schizophrenia research. Her multiple achievements have been acknowledged by membership at the Swiss Academy of Medical Science and numerous awards including the NARSAD Independent Investigator Award from the Brain & Behavior Research Foundation (USA) in 2006, the NARSAD Distinguished Investigator Award in 2010 and, in 2018, the SIRS Outstanding Basic Science Award from the Schizophrenia International Research Society.
Complete list of publications: https://orcid.org/0000-0003-1968-1646
22nd Paul Janssen Lecture 2023, Institute of Psychiatry, Psychology & Neuroscience, King’s College London: www.kcl.ac.uk/ioppn/paul-janssen-lecture

*Alessandro Serretti1 (1. Department of Biomedical and Neuromotor Sciences (DIBINEM), University of Bologna, Bologna, Italy)

Prof. Alessandro Serretti MD, PhD, is Professor of Psychiatry at Kore University of Enna, Italy and co-ordinates a research unit active in clinical and genetic studies of major psychoses.
He has authored more than 700 scientific papers in peer reviewed journals, one textbook of psychiatry and over 700 presentations at meetings. H-Index of 102. Editor in Chief of International Clinical Psychopharmacology. Highly Cited Researcher Web of Science. Reviewer or member of the editorial board for 170 journals and funding agencies.

*Zhen Wang1 (1. Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine)

Dr Zhen Wang is the current Vice President of the Shanhai Mental Health Center. Shanghai Jiao Tong University School of Medicine. He has actively pursued research in the fields of the neurobiological and psychological basis of obsessive compulsive disorder, anxiety disorders and traumatic stress related disorders for more than twenty years. He has applied structural and functional neuroimaging as well as biochemical analysis in the studies of these disorders and those at genetic risk. His psychological research has focused on personality, childhood trauma, perceived stress and cognitive function. He established the first OCD center in China and initiated the establishment of the Chinese OCD Treatment Network. Recently, he has focused on developing treatment approaches to refractory psychiatric disorders using neuromodulation such as Deep Brain Stimulation (DBS) and Transcranial Magnetic Stimulation (TMS)
×

Authentication

Abstract password authentication.
Password is required to view the abstract. Please enter a password to authenticate.

×

Please log in with your participant account.
» Participant Log In